腎細胞癌(RCC)患者を対象としたベルズチファン(MK-6482)およびザンザリンチニブの臨床試験(LITESPARK-034/LS-034/MK-6482-034)
PD-1/L1およびVEGF-TKI療法を順次または併用で実施後に進行した進行性腎細胞癌(RCC)患者を対象とした、ベルズチファン+ザンザリンチニブ対ベルズチファン+プラセボの第III相ランダム化二重盲検試験(LITESPARK-034)
Researchers are looking for new ways to treat advanced renal cell carcinoma (RCC).
A standard (usual) treatment for certain people with RCC is belzutifan (a study medicine), which is a targeted therapy. Targeted therapy is a treatment that works to control how specific types of cancer cells grow and spread. Researchers want to learn if adding another targeted therapy called zanzalintinib (another study medicine) can treat more people with advanced RCC than belzutifan alone.
The goal of this study is to learn if people who receive belzutifan and zanzalintinib live longer overall and without the cancer getting worse compared to people who receive belzutifan and placebo.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
研究の種類
研究の種類
入学 (推定)
入学
段階
段階
- フェーズ 3
連絡先と場所
研究連絡先
研究連絡先
- 名前:Toll Free Number
- 電話番号:1-888-577-8839
- メール:Trialsites@msd.com
研究場所
-
-
California
-
Duarte、California、アメリカ、91010
- 募集
- City of Hope Comprehensive Cancer Center ( Site 0129)
-
コンタクト:
- Study Coordinator
- 電話番号:877-817-9982
-
Irvine、California、アメリカ、92618
- 募集
- City of Hope Lennar Foundation Cancer Center ( Site 0142)
-
コンタクト:
- Study Coordinator
- 電話番号:see site 0129
-
-
Georgia
-
Marietta、Georgia、アメリカ、30060
- 募集
- Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital ( Site 0102)
-
コンタクト:
- Study Coordinator
- 電話番号:770-281-5124
-
-
Kentucky
-
Louisville、Kentucky、アメリカ、40202
- 募集
- University of Louisville, James Graham Brown Cancer Center ( Site 0133)
-
コンタクト:
- Study Coordinator
- 電話番号:502-562-4673
-
Louisville、Kentucky、アメリカ、40207
- 募集
- Norton Women's and Children's Hospital-Norton Cancer Institute - St. Matthews ( Site 0104)
-
コンタクト:
- Study Coordinator
- 電話番号:502-899-3366
-
-
Massachusetts
-
Boston、Massachusetts、アメリカ、02215
- 募集
- Beth Israel Deaconess Medical Center ( Site 0139)
-
コンタクト:
- Study Coordinator
- 電話番号:617-667-7000
-
Boston、Massachusetts、アメリカ、02215
- 募集
- Dana Farber Cancer Institute ( Site 0135)
-
コンタクト:
- Study Coordinator
- 電話番号:617-632-3000
-
-
Michigan
-
Grand Rapids、Michigan、アメリカ、49503
- 募集
- The Cancer and Hematology Centers ( Site 0123)
-
コンタクト:
- Study Coordinator
- 電話番号:616-954-9800
-
-
Missouri
-
St Louis、Missouri、アメリカ、63110
- 募集
- Washington University School of Medicine ( Site 0114)
-
コンタクト:
- Study Coordinator
- 電話番号:314-362-7355
-
-
New Jersey
-
Hackensack、New Jersey、アメリカ、07601
- 募集
- John Theurer Cancer Center at Hackensack University Medical Center ( Site 0108)
-
コンタクト:
- Study Coordinator
- 電話番号:551-996-5900
-
Morristown、New Jersey、アメリカ、07960
- 募集
- Atlantic Health System Morristown Medical Center ( Site 0109)
-
コンタクト:
- Study Coordinator
- 電話番号:973-971-7960
-
-
New York
-
New York、New York、アメリカ、10065
- 募集
- Memorial Sloan Kettering Cancer Center ( Site 0126)
-
コンタクト:
- Study Coordinator
- 電話番号:347-798-9213
-
-
Tennessee
-
Germantown、Tennessee、アメリカ、38138
- 募集
- The West Clinic, P.C. ( Site 0115)
-
コンタクト:
- Study Coordinator
- 電話番号:901-683-0055
-
-
Texas
-
Dallas、Texas、アメリカ、75390
- 募集
- UT Southwestern Medical Center ( Site 0119)
-
コンタクト:
- Study Coordinator
- 電話番号:214-648-3111
-
-
-
-
-
CABA、アルゼンチン、C1426ANZ
- 募集
- Instituto Alexander Fleming ( Site 0252)
-
コンタクト:
- Study Coordinator
- 電話番号:+541132218900
-
La Rioja、アルゼンチン、X5004BAL
- 募集
- Centro Oncológico Riojano Integral ( Site 0256)
-
コンタクト:
- Study Coordinator
- 電話番号:+543804436443X108
-
San Juan、アルゼンチン、J5402BGA
- 募集
- COE (Centro Oncológico de Excelencia) ( Site 0259)
-
コンタクト:
- Study Coordinator
- 電話番号:+54 2644229585
-
-
Buenos Aires
-
CABA、Buenos Aires、アルゼンチン、C1426AHB
- 募集
- Centro Oncologico Korben ( Site 0254)
-
コンタクト:
- Study Coordinator
- 電話番号:+541159507952
-
Ciudad de Buenos Aires、Buenos Aires、アルゼンチン、1181
- 募集
- Hospital Italiano de Buenos Aires ( Site 0253)
-
コンタクト:
- Study Coordinator
- 電話番号:+541149590200
-
Mar del Plata、Buenos Aires、アルゼンチン、B7600FZO
- 募集
- Instituto de Investigaciones Clinicas Mar del Plata ( Site 0250)
-
コンタクト:
- Study Coordinator
- 電話番号:+542234963224
-
-
Córdoba Province
-
Río Cuarto、Córdoba Province、アルゼンチン、X5800ALB
- 募集
- Centro Privado de RMI Río Cuarto S.A. II ( Site 0255)
-
コンタクト:
- Study Coordinator
- 電話番号:+543584620273
-
-
Santa Fe Province
-
Rosario、Santa Fe Province、アルゼンチン、S2000DSV
- 募集
- Sanatorio Parque ( Site 0251)
-
コンタクト:
- Study Coordinator
- 電話番号:+5493416955611
-
Rosario、Santa Fe Province、アルゼンチン、S2000KZE
- 募集
- Instituto de Oncología de Rosario ( Site 0257)
-
コンタクト:
- Study Coordinator
- 電話番号:+543414484830
-
-
-
-
-
Birmingham、イギリス、B15 2GW
- 募集
- University Hospitals Birmingham NHS Foundation Trust ( Site 2610)
-
コンタクト:
- Study Coordinator
- 電話番号:+4407789651543
-
Cardiff、イギリス、CF14 2TL
- 募集
- Velindre Cancer Centre ( Site 2612)
-
コンタクト:
- Study Coordinator
- 電話番号:+442920615888
-
Southampton、イギリス、SO16 6YD
- 募集
- University Hospital of Southampton ( Site 2606)
-
コンタクト:
- Study Coordinator
- 電話番号:023 8077 7222
-
-
Cambridgeshire
-
Cambridge、Cambridgeshire、イギリス、CB2 0QQ
- 募集
- Addenbrookes Hospital ( Site 2605)
-
コンタクト:
- Study Coordinator
- 電話番号:+441223805000
-
-
Edinburgh, City of
-
Edinburgh、Edinburgh, City of、イギリス、EH4 2XU
- 募集
- Western General Hospital ( Site 2608)
-
コンタクト:
- Study Coordinator
- 電話番号:+441315371398
-
-
Glasgow City
-
Glasgow、Glasgow City、イギリス、G12 0YN
- 募集
- The Beatson West of Scotland Cancer Centre ( Site 2602)
-
コンタクト:
- Study Coordinator
- 電話番号:+441413019916
-
-
Leicestershire
-
Leicester、Leicestershire、イギリス、LE1 5WW
- 募集
- Leicester Royal Infirmary ( Site 2604)
-
コンタクト:
- Study Coordinator
- 電話番号:0300 303 1573
-
-
London, City of
-
Northwood、London, City of、イギリス、HA6 2RN
- 募集
- Mount Vernon Hospital ( Site 2607)
-
コンタクト:
- Study Coordinator
- 電話番号:+4401923826111
-
-
Manchester
-
Withington、Manchester、イギリス、M20 4BX
- 募集
- The Christie Hospital NHS Foundation Trust ( Site 2601)
-
コンタクト:
- Study Coordinator
- 電話番号:0161 918 2546
-
-
-
-
-
Haifa、イスラエル、3109601
- 募集
- Rambam Health Care Campus ( Site 1600)
-
コンタクト:
- Study Coordinator
- 電話番号:+97247772688
-
Kfar Saba、イスラエル、4428164
- 募集
- Meir Medical Center. ( Site 1603)
-
コンタクト:
- Study Coordinator
- 電話番号:+97297472555
-
Petah Tikva、イスラエル、4941492
- 募集
- Rabin Medical Center ( Site 1602)
-
コンタクト:
- Study Coordinator
- 電話番号:97239378074
-
Ramat Gan、イスラエル、5265601
- 募集
- Sheba Medical Center ( Site 1601)
-
コンタクト:
- Study Coordinator
- 電話番号:97235303030
-
-
-
-
-
Bari、イタリア、70124
- 募集
- Azienda Ospedaliera Policlinico di Bari ( Site 1802)
-
コンタクト:
- Study Coordinator
- 電話番号:00390805593767
-
Bologna、イタリア、40138
- 募集
- IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola ( Site 1803)
-
コンタクト:
- Study Coordinator
- 電話番号:+390512142204
-
Milan、イタリア、20133
- 募集
- Fondazione IRCCS Istituto Nazionale dei Tumori ( Site 1800)
-
コンタクト:
- Study Coordinator
- 電話番号:02 2390 3028
-
Perugia、イタリア、06132
- 募集
- AO Santa Maria della Misericordia ( Site 1805)
-
コンタクト:
- Study Coordinator
- 電話番号:+39 0755784188
-
Roma、イタリア、00168
- 募集
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Università Cattolica del Sacro Cuore ( Site 1801)
-
コンタクト:
- Study Coordinator
- 電話番号:00390630155202
-
Roma、イタリア、00144
- 募集
- Istituto Nazionale Tumori Regina Elena ( Site 1804)
-
コンタクト:
- Study Coordinator
- 電話番号:+39 0652666919
-
-
Emilia-Romagna
-
Meldola、Emilia-Romagna、イタリア、47014
- 募集
- IRCCS - Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori" ( Site 1809)
-
コンタクト:
- Study Coordinator
- 電話番号:+390543739100
-
-
Milano
-
Rozzano、Milano、イタリア、20089
- 募集
- Istituto Clinico Humanitas ( Site 1808)
-
コンタクト:
- Study Coordinator
- 電話番号:0282244061
-
-
Treviso
-
Castelfranco Veneto、Treviso、イタリア、31033
- 募集
- Istituto Oncologico Veneto IRCCS ( Site 1806)
-
コンタクト:
- Study Coordinator
- 電話番号:+39 0423732336
-
-
Tuscany
-
Florence、Tuscany、イタリア、50134
- 募集
- Azienda Ospedaliera Universitaria Careggi ( Site 1807)
-
コンタクト:
- Study Coordinator
- 電話番号:+390557949648
-
-
-
-
Limburg
-
Maastricht、Limburg、オランダ、6229 HX
- 募集
- Maastricht UMC+ ( Site 1901)
-
コンタクト:
- Study Coordinator
- 電話番号:+31433877025
-
-
North Holland
-
Amsterdam、North Holland、オランダ、1066 CX
- 募集
- Nederlands Kanker Instituut Antoni van Leeuwenhoek (NKI AVL) ( Site 1900)
-
コンタクト:
- Study Coordinator
- 電話番号:+3120 512 9111
-
-
South Holland
-
Schiedam、South Holland、オランダ、3118 JH
- 募集
- Franciscus Gasthuis & Vlietland, Locatie Vlietland ( Site 1903)
-
コンタクト:
- Study Coordinator
- 電話番号:+31108931441
-
The Hague、South Holland、オランダ、2545 AA
- 募集
- Haga Ziekenhuis locatie Leyweg ( Site 1906)
-
コンタクト:
- Study Coordinator
- 電話番号:+3170 210 2143
-
-
-
-
New South Wales
-
Macquarie University、New South Wales、オーストラリア、2109
- 一時停止
- Macquarie University ( Site 2700)
-
-
Queensland
-
Woolloongabba、Queensland、オーストラリア、4102
- 一時停止
- Princess Alexandra Hospital ( Site 2703)
-
-
Victoria
-
Melbourne、Victoria、オーストラリア、3000
- 一時停止
- Peter MacCallum Cancer Centre ( Site 2702)
-
-
Western Australia
-
Murdoch、Western Australia、オーストラリア、6150
- 一時停止
- Fiona Stanley Hospital ( Site 2704)
-
-
-
-
Ontario
-
Ottawa、Ontario、カナダ、K1H 8L6
- 募集
- The Ottawa Hospital Cancer Centre ( Site 0003)
-
コンタクト:
- Study Coordinator
- 電話番号:613-737-7700
-
-
Quebec
-
Québec、Quebec、カナダ、G1J 1Z4
- 募集
- Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus ( Site 0001)
-
コンタクト:
- Study Coordinator
- 電話番号:418-525-4444
-
-
-
-
Attica
-
Athens、Attica、ギリシャ、185 47
- 募集
- Metropolitan Hospital ( Site 1402)
-
コンタクト:
- Study Coordinator
- 電話番号:+302104809667
-
Athens、Attica、ギリシャ、124 62
- 募集
- ATTIKON GENERAL UNIVERSITY HOSPITAL ( Site 1401)
-
コンタクト:
- Study Coordinator
- 電話番号:+302105832549
-
Athens、Attica、ギリシャ、115 28
- 募集
- Alexandra General Hospital of Athens ( Site 1400)
-
コンタクト:
- Study Coordinator
- 電話番号:+302132162543
-
-
-
-
-
Barcelona、スペイン、08035
- 募集
- Hospital Universitari Vall d Hebron ( Site 2303)
-
コンタクト:
- Study Coordinator
- 電話番号:+34934894350
-
Las Palmas、スペイン、35016
- 募集
- Hospital Insular de Gran Canaria ( Site 2308)
-
コンタクト:
- Study Coordinator
- 電話番号:+34928441738
-
Madrid、スペイン、28041
- 募集
- Hospital Universitario 12 de Octubre ( Site 2300)
-
コンタクト:
- Study Coordinator
- 電話番号:+34913908339
-
Valencia、スペイン、46009
- 募集
- Fundación Instituto Valenciano de Oncología ( Site 2307)
-
コンタクト:
- Study Coordinator
- 電話番号:+34961114229
-
-
Andalusia
-
Seville、Andalusia、スペイン、41013
- 募集
- Hospital Universitario Virgen del Rocio ( Site 2306)
-
コンタクト:
- Study Coordinator
- 電話番号:+34955013068
-
-
Barcelona
-
L'Hospitalet de Llobregat、Barcelona、スペイン、08908
- 募集
- Institut Català d'Oncologia - L'Hospitalet ( Site 2305)
-
コンタクト:
- Study Coordinator
- 電話番号:+34932607744
-
-
Madrid, Comunidad de
-
Madrid、Madrid, Comunidad de、スペイン、28007
- 募集
- HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑON ( Site 2301)
-
コンタクト:
- Study Coordinator
- 電話番号:+34914269393
-
-
-
-
-
Hradec Králové、チェコ、500 05
- 募集
- Fakultni nemocnice Hradec Kralove ( Site 0902)
-
コンタクト:
- Study Coordinator
- 電話番号:+420727854666
-
Olomouc、チェコ、779 00
- 募集
- Fakultni nemocnice Olomouc ( Site 0901)
-
コンタクト:
- Study Coordinator
- 電話番号:+420588445923
-
Prague、チェコ、150 06
- 募集
- Fakultni nemocnice v Motole ( Site 0900)
-
コンタクト:
- Study Coordinator
- 電話番号:+420734236410
-
Prague、チェコ、128 08
- 募集
- Fakulti poliklinika ( Site 0906)
-
コンタクト:
- Study Coordinator
- 電話番号:+420224966405
-
-
Brno-mesto
-
Brno、Brno-mesto、チェコ、656 53
- 募集
- Masarykuv onkologicky ustav ( Site 0903)
-
コンタクト:
- Study Coordinator
- 電話番号:+420543132216
-
-
Ostrava Mesto
-
Ostrava、Ostrava Mesto、チェコ、708 52
- 募集
- Fakultni nemocnice Ostrava ( Site 0904)
-
コンタクト:
- Study Coordinator
- 電話番号:+420597374322
-
-
-
-
Coquimbo Region
-
La Serena、Coquimbo Region、チリ、1720430
- 募集
- IC La Serena Research ( Site 0405)
-
コンタクト:
- Study Coordinator
- 電話番号:56958646664
-
-
Los Lagos Region
-
Port Montt、Los Lagos Region、チリ、5500243
- 募集
- Clínica Puerto Montt ( Site 0404)
-
コンタクト:
- Study Coordinator
- 電話番号:+56985383586
-
-
Region M. de Santiago
-
Santiago、Region M. de Santiago、チリ、7500921
- 募集
- Fundacion Arturo Lopez Perez ( Site 0401)
-
コンタクト:
- Study Coordinator
- 電話番号:56224205098
-
Santiago、Region M. de Santiago、チリ、8420383
- 募集
- Bradfordhill ( Site 0400)
-
コンタクト:
- Study Coordinator
- 電話番号:56229490970
-
-
Valparaiso
-
Viña del Mar、Valparaiso、チリ、2520598
- 募集
- ONCOCENTRO APYS ( Site 0403)
-
コンタクト:
- Study Coordinator
- 電話番号:56323320850
-
-
-
-
Capital Region
-
Herlev、Capital Region、デンマーク、2730
- 募集
- Herlev Hospital ( Site 1002)
-
コンタクト:
- Study Coordinator
- 電話番号:00 45 38689191
-
-
Central Jutland
-
Aarhus、Central Jutland、デンマーク、8200
- 募集
- Aarhus Universitetshospital, Skejby ( Site 1001)
-
コンタクト:
- Study Coordinator
- 電話番号:+4591167472
-
-
Region Syddanmark
-
Odense、Region Syddanmark、デンマーク、5000
- 募集
- Odense Universitets Hospital ( Site 1000)
-
コンタクト:
- Study Coordinator
- 電話番号:+4566113333
-
-
-
-
-
Adana、トルコ(Türkiye)、01140
- 募集
- Adana Medical Park Seyhan Hastanesi ( Site 2505)
-
コンタクト:
- Study Coordinator
- 電話番号:+905372688986
-
Ankara、トルコ(Türkiye)、06620
- 募集
- Ankara University Health Practice and Research Hospitals ( Site 2506)
-
コンタクト:
- Study Coordinator
- 電話番号:+90 312 595 71 12
-
Edirne、トルコ(Türkiye)、22030
- 募集
- Trakya University Medical Faculty Hospital ( Site 2502)
-
コンタクト:
- Study Coordinator
- 電話番号:+9005378528123
-
Istanbul、トルコ(Türkiye)、34010
- 募集
- Koc Universitesi Hastanesi ( Site 2501)
-
コンタクト:
- Study Coordinator
- 電話番号:0090 850 250 8 250
-
Izmir、トルコ(Türkiye)、35080
- 募集
- Ege Universitesi Hastanesi ( Site 2503)
-
コンタクト:
- Study Coordinator
- 電話番号:0 232 343 43 43
-
-
Ankara
-
Sıhhiye、Ankara、トルコ(Türkiye)、06230
- 募集
- Hacettepe Universite Hastaneleri ( Site 2500)
-
コンタクト:
- Study Coordinator
- 電話番号:+905439340493
-
-
-
-
-
Berlin、ドイツ、10117
- 募集
- Charité Universitaetsmedizin Berlin - Campus Mitte ( Site 1312)
-
コンタクト:
- Study Coordinator
- 電話番号:+4930450515288
-
-
Bavaria
-
Augsburg、Bavaria、ドイツ、86156
- 募集
- Universitaetsklinikum Augsburg ( Site 1316)
-
コンタクト:
- Study Coordinator
- 電話番号:+498214002348
-
Munich、Bavaria、ドイツ、81675
- 募集
- klinikum rechts der isar der technischen universität münchen ( Site 1315)
-
コンタクト:
- Study Coordinator
- 電話番号:00498941402522
-
-
Thuringia
-
Jena、Thuringia、ドイツ、07747
- 募集
- Universitätsklinikum Jena ( Site 1313)
-
コンタクト:
- Study Coordinator
- 電話番号:+4936419329970
-
-
-
-
Alpes-Maritimes
-
Nice、Alpes-Maritimes、フランス、06189
- 募集
- Centre Antoine Lacassagne ( Site 1209)
-
コンタクト:
- Study Coordinator
- 電話番号:+33492031538
-
-
Bouches-du-Rhone
-
Marseille、Bouches-du-Rhone、フランス、13003
- 募集
- Hopital Europeen Marseille ( Site 1216)
-
コンタクト:
- Study Coordinator
- 電話番号:+33413427427
-
-
Haute-Garonne
-
Toulouse、Haute-Garonne、フランス、31059
- 募集
- LBM ONCOPOLE CLAUDIUS REGAUD ( Site 1215)
-
コンタクト:
- Study Coordinator
- 電話番号:+33531155050
-
-
Maine-et-Loire
-
Angers、Maine-et-Loire、フランス、49933
- 募集
- CHU Angers ( Site 1204)
-
コンタクト:
- Study Coordinator
- 電話番号:+33241354694
-
-
Pays de la Loire Region
-
Le Mans、Pays de la Loire Region、フランス、72000
- 募集
- Clinique Victor Hugo Le Mans-Oncology-Radiotherapy ( Site 1203)
-
コンタクト:
- Study Coordinator
- 電話番号:+33 243297908
-
Saint Priest En Jarez、Pays de la Loire Region、フランス、42271
- 募集
- CHU de Saint-Etienne ( Site 1202)
-
コンタクト:
- Study Coordinator
- 電話番号:+33477917082
-
-
Val-de-Marne
-
Villejuif、Val-de-Marne、フランス、94800
- 募集
- Gustave Roussy ( Site 1214)
-
コンタクト:
- Study Coordinator
- 電話番号:+33142114211
-
-
-
-
Espírito Santo
-
Vitória、Espírito Santo、ブラジル、29055-450
- 募集
- CEDOES ( Site 0303)
-
コンタクト:
- Study Coordinator
- 電話番号:+552721250202
-
-
Paraná
-
Curitiba、Paraná、ブラジル、80510-130
- 募集
- Instituto do Câncer e Transplante de Curitiba ( Site 0300)
-
コンタクト:
- Study Coordinator
- 電話番号:+55 41 99205-7755
-
-
Rio Grande do Norte
-
Natal、Rio Grande do Norte、ブラジル、59062-000
- 募集
- Liga Norte Riograndense Contra o Câncer ( Site 0307)
-
コンタクト:
- Study Coordinator
- 電話番号:+55 84 4009-5595
-
-
São Paulo
-
Ribeirão Preto、São Paulo、ブラジル、14026-610
- 募集
- Hope - Humanizacao Em Oncologia, Pesquisa E Ensino ( Site 0306)
-
コンタクト:
- Study Coordinator
- 電話番号:+55 16 3913-8181
-
São José do Rio Preto、São Paulo、ブラジル、15090-000
- 募集
- Fundação Faculdade Regional de Medicina de São José do Rio Preto ( Site 0302)
-
コンタクト:
- Study Coordinator
- 電話番号:+55 17 3201-5054
-
-
-
-
Greater Poland Voivodeship
-
Skórzewo、Greater Poland Voivodeship、ポーランド、60-185
- 募集
- AIDPORT Sp. z o.o. ( Site 2118)
-
コンタクト:
- Study Coordinator
- 電話番号:+48570783100
-
-
Lesser Poland Voivodeship
-
Krakow、Lesser Poland Voivodeship、ポーランド、30-727
- 募集
- Pratia MCM Krakow ( Site 2115)
-
コンタクト:
- Study Coordinator
- 電話番号:+48122958160
-
-
Masovian Voivodeship
-
Siedlce、Masovian Voivodeship、ポーランド、08-110
- 募集
- Mazowiecki Szpital Wojewódzki im. Sw. Jana Pawla II w Siedlcach Sp. z o.o. ( Site 2102)
-
コンタクト:
- Study Coordinator
- 電話番号:+48256403300
-
Warsaw、Masovian Voivodeship、ポーランド、02-172
- 募集
- MTZ Clinical Research Powered by Pratia ( Site 2107)
-
コンタクト:
- Study Coordinator
- 電話番号:+48225725959
-
Warsaw、Masovian Voivodeship、ポーランド、02-781
- 募集
- Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Nowotworów Układu Moczowego ( Site 2100)
-
コンタクト:
- Study Coordinator
- 電話番号:+48225462331
-
-
Silesian Voivodeship
-
Gliwice、Silesian Voivodeship、ポーランド、44-102
- 募集
- Narodowy Instytut Onkologii - Oddzial w Gliwicach ( Site 2106)
-
コンタクト:
- Study Coordinator
- 電話番号:+48322788237
-
-
-
-
-
Seoul、韓国、05505
- 募集
- Asan Medical Center ( Site 2901)
-
コンタクト:
- Study Coordinator
- 電話番号:+82-2-3010-5977
-
Seoul、韓国、06351
- 募集
- Samsung Medical Center ( Site 2902)
-
コンタクト:
- Study Coordinator
- 電話番号:+82-2-3410-1767
-
Seoul、韓国、03722
- 募集
- Severance Hospital, Yonsei University Health System ( Site 2903)
-
コンタクト:
- Study Coordinator
- 電話番号:+82-2-2228-8138
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
The main inclusion criteria include but are not limited to the following:
- Has a histologically confirmed diagnosis of unresectable, advanced renal cell carcinoma (RCC) with clear cell component (with or without sarcomatoid features) ie, Stage IV RCC per American Joint Committee on Cancer (8th Edition)
- Has measurable disease per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1)
- Has received no more than 3 prior systemic regimens for RCC, including only 1 prior anti-Programmed Cell Death-1/Programmed Cell Death 1 Ligand 1 therapy
Exclusion Criteria:
For exclusion criteria: The main exclusion criteria include but are not limited to the following:
- Has any of the following: a pulse oximeter reading <92% at rest, requires intermittent supplemental oxygen, or required chronic supplemental oxygen
- Has clinically significant cardiovascular disease within 12 months from first dose of study intervention
- Has deep vein thrombosis within 3 months before randomization unless stable, asymptomatic, and treated with therapeutic anticoagulation for at least 4 weeks before randomization
- Has a left ventricular ejection fraction ≤50% or below the institutional (or local laboratory) normal range as determined by multigated acquisition or echocardiogram
- Has had major surgery within 8 weeks before randomization
- Has current pneumonitis/interstitial lung disease
- Has a history of human immunodeficiency virus infection
- Has Hepatitis B or Hepatitis C virus infection
- Has a known additional malignancy that is progressing or has required active treatment within the past 3 years
- Has a history of solid organ transplant
- Has not adequately recovered from major surgery or has ongoing surgical complications
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:トリプル
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
実験的:Belzutifan + Zanzalintinib
Participants will receive 120 mg belzutifan orally and 60 mg zanzalintinib once daily for approximately 24 months. |
Tablet for oral administration.
他の名前:
Tablet for oral administration.
他の名前:
|
|
アクティブコンパレータ:Belzutifan + Placebo
Participants will receive 120 mg belzutifan orally and zanzalintinib-matching placebo once daily for approximately 24 months. |
Tablet for oral administration.
他の名前:
Zanzalintinib-matching placebo tablet for oral administration. |
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Progression-free Survival (PFS)
時間枠:Up to approximately 30 months
|
PFS is defined as the time from randomization to the first documented disease progression per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) based on blinded independent central review (BICR) or death due to any cause, whichever occurs first. |
Up to approximately 30 months
|
|
Overall Survival (OS)
時間枠:Up to approximately 50 months
|
OS is defined as the time from randomization to death due to any cause. |
Up to approximately 50 months
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Objective Response Rate (ORR)
時間枠:Up to approximately 30 months
|
ORR is defined as the percentage of participants who have achieved confirmed Complete Response (CR: disappearance of all target lesions) or a Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1 as assessed by BICR. |
Up to approximately 30 months
|
|
Duration of Response (DOR)
時間枠:Up to approximately 30 months
|
DOR is defined as the interval from the first documented evidence of a CR (disappearance of all target lesions) or a PR (at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1 until Progressive Disease (PD) or death due to any cause, whichever occurs first, in participants demonstrating a best confirmed response of CR or PR. Per RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. |
Up to approximately 30 months
|
|
Number of Participants Who Experience One or More Adverse Events (AEs)
時間枠:Up to approximately 25 months
|
An AE is any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE. The number of participants who experience an AE will be reported. |
Up to approximately 25 months
|
|
Number of Participants who Discontinue Study Treatment Due to an AE
時間枠:Up to approximately 24 months
|
An AE is any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE. The number of participants who discontinue study treatment due to an AE will be reported. |
Up to approximately 24 months
|
|
Change from Baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Global Health Status (Item 29) and Quality of Life (Item 30) Combined Score
時間枠:Baseline and up to approximately 25 months
|
EORTC QLQ-C30 is a questionnaire to assess the overall quality of life (QoL) of cancer patients. Participant responses to questions regarding Global Health Status (GHS; "How would you rate your overall health during the past week?") and QoL ("How would you rate your overall quality of life during the past week?") are scored on a 7-point scale (1= Very poor to 7=Excellent). The combined score of GHS (Item 29) and QoL (Item 30) is computed by averaging the raw scores of the 2 items and then applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. A higher score indicates a better outcome. The change from baseline in GHS and QoL combined score will be presented. |
Baseline and up to approximately 25 months
|
|
Change from Baseline in the EORTC QLQ-C30 Physical Functioning (Items 1-5) Combined Score
時間枠:Baseline and up to approximately 25 months
|
EORTC QLQ-C30 is a questionnaire to assess the overall QoL of cancer patients. Participant responses to 5 questions about their physical functioning (Items 1 to 5) are scored on a 4-point scale (1=Not at All to 4=Very Much). The combined score of items 1 to 5 was computed by averaging the raw scores of the 5 items and then applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. A higher score indicates a better outcome. The change from baseline in EORTC QLQ-C30 physical functioning (Items 1-5) combined score will be presented. |
Baseline and up to approximately 25 months
|
|
Change from Baseline in the EORTC QLQ-C30 Role Functioning (Items 6 and 7) Combined Score
時間枠:Baseline and up to approximately 25 months
|
The EORTC QLQ-C30 is a cancer specific health-related quality of life questionnaire. The role functioning score is based on participant responses to questions scored on a 4-point scale (1=Not at All to 4=Very Much). The combined score was computed by averaging the raw scores of Items 6 and 7 and then applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. Higher scores indicate better role functioning. The change from baseline in EORTC QLQ-C30 Role Functioning (Items 6 and 7) combined score will be reported. |
Baseline and up to approximately 25 months
|
|
Change From Baseline in Disease Symptoms Using the Functional Assessment of Cancer Therapy-Kidney Symptom Index-Disease-related Symptoms (FKSI-DRS) (Items 1-9) Score
時間枠:Baseline and up to approximately 25 months
|
The FKSI-DRS index consists of a 9-item questionnaire that assesses the extent of participant symptoms from kidney cancer. Each item is scored on a 5-point scale (0=not at all to 4=very much). FKSI-DRS total score ranged from 0 (most severe symptoms) to 36 (no symptoms) with a higher score indicating a better outcome. |
Baseline and up to approximately 25 months
|
|
Time to Deterioration (TTD) in EORTC QLQ-C30 Global Health Status (Item 29) and Quality of Life (Item 30) Combined Score
時間枠:Up to approximately 25 months
|
EORTC QLQ-C30 is a questionnaire to assess QoL of cancer patients. Participant responses to questions on GHS ("How would you rate your overall health during the past week?") and QoL ("How would you rate your overall QoL during the past week?") were scored on a 7-point scale (1= Very poor to 7=Excellent). The combined score of GHS (Item 29) and QoL (Item 30) was computed by averaging raw scores of the 2 items and applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. A higher score indicates a better outcome. TTD was defined as the time from baseline to first onset of ≥10-point negative change (decrease) from baseline in GHS-QoL combined score. A longer TTD indicates a better outcome. |
Up to approximately 25 months
|
|
TTD in EORTC QLQ-C30 Physical Functioning (Items 1-5) Score
時間枠:Up to approximately 25 months
|
EORTC QLQ-C30 is a questionnaire to assess the overall QoL of cancer patients. Participant responses to 5 questions about their physical functioning (Items 1 to 5) are scored on a 4-point scale (1=Not at All to 4=Very Much). The combined score of items 1 to 5 was computed by averaging the raw scores of the 5 items and then applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. A higher score indicates a better outcome. TTD was defined as the time from baseline to first onset of ≥10-point negative change (decrease) from baseline in physical functioning (Items 1 to 5). A longer TTD indicates a better outcome. |
Up to approximately 25 months
|
|
TTD in EORTC QLQ-C30 Role Functioning (Items 6 and 7) Score
時間枠:Up to approximately 25 months
|
EORTC QLQ-C30 is a questionnaire to assess the overall QoL of cancer patients. Participant responses to questions about their role functioning (Items 6 and 7) are scored on a 4-point scale (1=Not at All to 4=Very Much). The combined score of Items 6 and 7 was computed by averaging the raw scores of the items and then applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. A higher score indicates a better outcome. TTD was defined as the time from baseline to first onset of ≥10-point negative change (decrease) from baseline in role functioning (Items 6 and 7). A longer TTD indicates a better outcome. |
Up to approximately 25 months
|
|
TTD in Disease Symptoms Using the FKSI-DRS (Items 1-9) Score
時間枠:Up to approximately 25 months
|
TTD is defined as time from the first dose of study treatment to the date of deterioration of FKSI-DRS score. The FKSI-DRS index consists of a 9-item questionnaire that assesses the extent of participant symptoms from kidney cancer. Each item is scored on a 5-point scale (0=not at all to 4=very much). FKSI-DRS total score ranged from 0 (most severe symptoms) to 36 (no symptoms) with a higher score indicating a better outcome. Deterioration is defined as a 3-point decrease (i.e. lower score) in symptom score and the time to true deterioration is the time to first onset of 3 or more decreases from baseline with confirmation under right-censoring rule (the last observation). A longer TTD indicates a better outcome. |
Up to approximately 25 months
|
協力者と研究者
捜査官
捜査官
- スタディディレクター:Medical Director、Merck Sharp & Dohme LLC
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
その他の研究ID番号
- 6482-034
- U1111-1311-4692 (レジストリ識別子:UTN)
- 2024-516993-31-00 (レジストリ識別子:EU CT)
- LITESPARK-034 (その他の識別子:MSD)
- MK-6482-034 (その他の識別子:MSD)
- LS-034 (その他の識別子:MSD)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。